![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, Melbourne, Florida (P.P., J.R.A., J.R.); Meakins-Christie Laboratories, Department of Medicine, McGill University, Montreal, Quebec, Canada (C.C., S.G., W.S.P.); and Mass Spectrometry Unit, McGill University, Montreal, Quebec, Canada (A.L., O.A.M.)
Received December 5, 2007; accepted February 20, 2008.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). LTB4, acting through the BLT1 receptor, is a potent activator of neutrophils and lymphocytes. LTD4 interacts with the cysteinyl-LT1 and cysteinyl-LT2 receptors to stimulate smooth muscle contraction, cytokine release from leukocytes, and various other responses. Although 5-HETE itself has only relatively weak biological activities, it is oxidized to the potent granulocyte chemoattractant 5-oxo-ETE by the action of 5-hydroxyeicosanoid dehydrogenase (5-HEDH) (Powell and Rokach, 2005). 5-HEDH is a microsomal enzyme that is dependent on NADP+ as an electron acceptor. This limits its activity because NADP+, in contrast to its reduced form NADPH, is only present at low concentrations within cells. Thus, 5-oxo-ETE synthesis from arachidonic acid requires both activation of 5-LO in conjunction with increased NADP+ levels, which can be induced by oxidative stress and, in phagocytic cells, by activation of the respiratory burst. 5-HEDH is present in most types of leukocytes (Powell and Rokach, 2005) as well as endothelial (Erlemann et al., 2006) and epithelial cells (Erlemann et al., 2007).
5-Oxo-ETE induces a variety of rapid responses in neutrophils and eosinophils, including calcium mobilization, actin polymerization, CD11b expression, and L-selectin shedding (Powell and Rokach, 2005). It also stimulates superoxide production and degranulation in neutrophils primed with tumor necrosis factor-
(O'Flaherty et al., 1994) or granulocyte macrophage colony-stimulating factor (O'Flaherty et al., 1996). It is a potent chemoattractant for both neutrophils (Powell et al., 1993) and eosinophils (Powell et al., 1995a) and induces transendothelial migration of eosinophils (Dallaire et al., 2003). It also has modest chemoattractant effects on monocytes and stimulates actin polymerization (but not calcium mobilization) (Sozzani et al., 1996) and granulocyte macrophage colony-stimulating factor release (Stamatiou et al., 2004) in these cells. When administered in vivo to Brown Norway rats by intratracheal instillation, 5-oxo-ETE elicits pulmonary eosinophilia (Stamatiou et al., 1998). In humans, it induces the infiltration of both eosinophils and neutrophils into the skin (Almishri et al., 2005). In addition to its effects on inflammatory cells, 5-oxo-ETE has been reported to block the induction of apoptosis in prostate tumor cells by MK886 (Ghosh and Myers, 1998) and selenium (Ghosh, 2004).
|
|
|
|
|
|
). This receptor is expressed on eosinophils, neutrophils, and monocytes (Hosoi et al., 2002; Jones et al., 2003) and has also been reported to be present on prostate tumor cells but not on normal prostate epithelial cells (Sundaram and Ghosh, 2006). Metabolism of 5-oxo-ETE by a variety of pathways, including reduction back to 5-HETE by 5-HEDH, reduction of the 6,7-double bond by a 
6-reductase, conversion to 5-oxo-12-HETE by 12-lipoxygenase, and 
-oxidation by LTB4 20-hydroxylase, results in dramatic reductions in OXE-receptor agonist activity (Powell and Rokach, 2005). However, the relationship of biological activity to carbon chain length and the presence or absence of the 8, 11, and 14 double bonds is unknown. Because such knowledge is critical for the design of potent OXE-receptor agonists and antagonists, we prepared a series of 5-oxo-ETE analogs with different chain lengths and numbers of double bonds and investigated their potencies in eliciting biological responses in neutrophils and eosinophils. |
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). 5-Oxo-20:5 was prepared by incubation of the corresponding 5-hydroxy compound (5-HEPE; obtained from Cayman Chemical, Ann Arbor, MI) with a microsomal fraction from human neutrophils in the presence of NADP+ as described previously (Powell et al., 1995b). All of the other 5-oxo fatty acids shown in Fig. 1 as well as 5-hydroxy-20:3 were prepared by total chemical synthesis using methods that will be published separately. The structures were confirmed by nuclear magnetic resonance and mass spectrometry. All compounds were purified by reversed-phase high-performance liquid chromatography (RP-HPLC) within 1 month of use. 13-HODE was prepared by oxidation of linoleic acid with soybean lipoxygenase type 1B (Sigma-Aldrich, St. Louis, MO) (Hamberg and Samuelsson, 1967). Other Reagents. Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma-Aldrich, whereas NADP+ and A23187 [GenBank] were obtained from Roche Diagnostics (Laval, QC, Canada) and Calbiochem (La Jolla, CA), respectively. Dimethyl sulfoxide was purchased from Fisher Scientific (Nepean, ON, Canada).
Preparation of Neutrophils. Neutrophils were purified from whole blood as described previously using dextran 500 (from Leuconostoc; Sigma-Aldrich) to remove red blood cells followed by centrifugation over Ficoll-Paque (GE Healthcare, Baie d'Urfe, QC Canada) to remove mononuclear cells and hypotonic lysis of any remaining red blood cells (Powell et al., 1992). The neutrophils were suspended in phosphate-buffered saline (PBS).
Measurement of Calcium Mobilization in Neutrophils. Intracellular calcium was measured in neutrophils loaded with indo-1 acetoxymethyl ester (Invitrogen, Carlsbad, CA) as described previously (Powell et al., 1996). The cells were washed and resuspended in PBS. Five minutes before commencing data acquisition, Ca2+ and Mg2+ were added to give final concentrations of 1.8 and 1 mM, respectively. After stabilization of the baseline, fluorescence was measured using a Deltascan 4000 spectrofluorometer (Photon Technology International, Birmingham, NJ) with a temperature-controlled cuvette holder equipped with a magnetic stirrer.
Evaluation of CD11b Expression in Neutrophils. CD11b expression was evaluated by flow cytometry (Powell et al., 1997) using a FACSCalibur instrument (BD Biosciences, San Jose, CA). Unfractionated leukocytes, prepared by treatment of whole blood with dextran followed by hypotonic lysis as described above, were incubated for 10 min with various concentrations of 5-oxo fatty acids. The cells were then stained with fluorescein isothiocyanate-labeled anti-CD11b (Beckman Coulter, Fullerton, CA), and neutrophils were identified on the basis of their forward- and side-scatter properties.
Measurement of Actin Polymerization in Eosinophils. F-actin was measured using unfractionated leukocytes prepared as described above. The leukocytes were first treated with PC5-labeled anti-CD16 (Beckman Coulter) to label neutrophils and then incubated with 5-oxo fatty acids for 20 s. The cells were then fixed with formaldehyde and stained by treatment with a mixture of lysophosphatidylcholine and NBD-phallacidin (Invitrogen) as described previously (Monneret et al., 2002). F-actin was then measured by flow cytometry in eosinophils, which were identified as a population of cells with high side scatter and low expression of CD16.
Neutrophil Migration. Neutrophil migration was measured using 48-well microchemotaxis chambers (Neuro Probe Inc., Cabin John, MD) and Sartorius cellulose nitrate filters (8-µm pore size, 140-µm thickness; Neuro Probe Inc.) as described previously (Powell et al., 1996). 5-Oxo fatty acids were added to the bottom wells, and neutrophils were added to the top wells. After 2 h, the filters were removed and stained, and the numbers of cells on the bottom surfaces were counted in five different fields at a magnification of 400x for each incubation, each of which was performed in triplicate.
Analysis of Metabolites of Mead Acid. A suspension of neutrophils (2 x 106 cells/ml) in PBS containing 1.8 mM Ca2+ and 1 mM Mg2+ was incubated with Mead acid (50 µM; Cayman Chemical) in the presence of A23187
[GenBank]
(5 µM) and PMA (50 nM). After various times, the incubations were terminated by addition of methanol (0.65 ml) containing 0.15% trifluoroacetic acid and cooling to 0°C. After addition of 13-HODE (100 ng) as an internal standard, the products were analyzed by automated precolumn extraction coupled to RP-HPLC (Powell, 1987) using a Waters Alliance system (Waters, Milford, MA). Products were quantitated by comparing the areas of their peaks of UV absorbance at their 
max with that of 13-HODE. The conditions for preparative experiments were similar, with the exception that 108 neutrophils in 20 ml were used, and the products were extracted manually on a C18 Sep-Pak (Waters) (Powell, 1980). A Novapak C18 column (3.9 x 150 mm; Waters) was used as the stationary phase, whereas the mobile phase was a linear gradient over 40 min between water/acetonitrile/methanol/acetic acid (60:30: 10:0.02) and water/acetonitrile/methanol/acetic acid (10:38:52:0.02) with a flow rate of 1 ml/min.
Mass Spectrometry. Mead acid metabolites were identified by Fourier transform mass spectrometry (FTMS) as described previously (Erlemann et al., 2007) using an IonSpec 7.0 Tesla instrument. MS/MS experiments were performed after isolating the monoisotopic parent ion using 500 ms of sustained off-resonance (1 kHz) irradiation collision-induced dissociation and a 90-ms nitrogen gas pulse.
Data Analysis. With the exception of EC20 and IC50 values, the values are expressed as the means ± S.E. of data from n independent experiments, as indicated in the figure legends. The concentration-response data are normalized and are expressed as percentages of the response to 1 µM 5-oxo-ETE for each individual experiment. "EC20" values are the concentrations of 5-oxo fatty acids that induced a response equal to 20% of the response to 1 µM 5-oxo-ETE (which was the maximal response to 5-oxo-ETE in the case of actin polymerization). IC50 values are the concentrations of 5-oxo fatty acids that inhibited the response to 5-oxo-ETE (10 nM) by 50%. Both EC20 and IC50 values are presented as geometric means with the 95% confidence intervals shown in brackets. The statistical significance of differences in EC20 and IC50 values and maximal responses was determined by one-way repeated-measured analysis of variance using the Bonferroni test as a multiple comparison method. Although it was not possible to test all of the compounds in the same experiment, a complete concentration-response curve to 5-oxo-ETE was done in each case. For the purposes of statistical analysis, the results for each of the 5-oxo fatty acids were compared with those for 5-oxo-ETE only from the same experiments.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The concentration-response curves for the effects of 5-oxo-ETE and other 5-oxo fatty acids on calcium mobilization are shown in Fig. 3. All of the compounds tested had 5-oxo substituents, but, for simplicity, only the carbon chain lengths and numbers of double bonds are indicated by the labels. The response to 5-oxo-ETE itself seems to be biphasic, tending toward a plateau at 1 µM but then increasing substantially at the highest concentration tested (10 µM) (Fig. 3A). A number of the other analogs tested also exhibited this type of concentration-response relationship, in which a plateau did not seem to have been reached by a concentration of 10 µM. For this reason, it was not possible to calculate precise EC50 values. Instead, EC20 values were calculated, but there was still considerable variability for some compounds that had low maximal responses (Table 1).
|
Figure 3A shows the effects on calcium mobilization of a series of 5-oxo-6-trans-8-cis dienoic acids between 12 and 20 carbons compared with that of 5-oxo-ETE. Among these dienoic acids, 5-oxo-18:2 gave the strongest response and was approximately 20 times more potent than 5-oxo-20:2. 5-Oxo-16:2 was much less active and seemed to have a considerably reduced maximal response compared with the longer-chain compounds. Neither 5-oxo-14:2 nor 5-oxo-12:2 induced a detectable calcium response. In Fig. 3B, the effects of 20-carbon 5-oxo fatty acids containing different numbers of double bonds are shown. 5-Oxo-20:3 is nearly as active as 5-oxo-ETE, but the response drops off considerably as the number of double bonds is reduced, with 5-oxo-20:1 having only weak agonist activity, and 5-oxo-20:0 displaying no detectable activity at the highest concentration tested (10 µM). The effects of three different 5-oxo-20:3 isomers and two 5-oxo-monoenoic fatty acids are compared in Fig. 3C. The responses to 5-oxo-20:3 (6E,8Z,11Z) and 8-trans-5-oxo-20:3 (6E,8E,11Z) are quite similar, with the exception that the 8-cis isomer tends to elicit a stronger response at lower concentrations, whereas the 8-trans isomer seems to induce a slightly higher maximal response. As observed for the dienoic acid series, 5-oxo-18:1 induces a stronger response than its C20 homolog.
Desensitization of 5-Oxo-ETE-Induced Calcium Mobilization by 5-Oxo Fatty Acids. The ability of each of the 5-oxo fatty acids to desensitize neutrophils to subsequent addition of 5-oxo-ETE (10 nM) was investigated. The rank order of potency for desensitization was similar to that for agonist activity. However, in this case, all of the analogs induced complete desensitization to 5-oxo-ETE, with the exception of 5-oxo-12:2, 5-oxo-14:2, and 5-oxo-20:0. Parallel concentration-response curves were obtained with well defined, maximal responses, permitting calculation of IC50 values (see Fig. 6). 5-Oxo-ETE, 5-oxo-20:3, 8-trans-5-oxo-20:3, and 5-oxo-18:2 all had very similar concentration-response curves (Fig. 3, D–F) with IC50 values of approximately 3 nM. 6E,8Z,14Z-5-Oxo-20:3 and 5-oxo-20:2 were approximately five to eight times less potent than 5-oxo-ETE in inducing desensitization to 5-oxo-ETE, whereas 5-oxo-16:2, 5-oxo-18:1, and 5-oxo-20:1 were approximately 100 to 150 times less potent. Only very modest responses were observed for 5-oxo-14:2 and 5-oxo-20:0 at the highest concentration tested (10 µM), whereas 5-oxo-12:2 was without any detectable activity (Fig. 3, D and E).
|
Effects of 5-Oxo Fatty Acids on Actin Polymerization in Eosinophils. The potencies of 5-oxo fatty acids in inducing actin polymerization in eosinophils were determined using flow cytometry. These cells were identified in unfractionated leukocyte preparations on the basis of minimal labeling with anti-CD16 and high side scatter. The use of unfractionated leukocytes has the advantage of reducing the number of manipulations to which the cells are subjected, thus lessening the chances of activation during cell preparation. Although it is theoretically possible that the responses of eosinophils could have been mediated by the release of stimulating factors from neutrophils, this would seem unlikely because of the very rapid actin polymerization response, which was determined after incubation with agonists for only 20 s.
In contrast to their effects on calcium mobilization and CD11b expression, the responses to most of the compounds tested reached plateaus. However, the maximal responses to some of the analogs were considerably lower than that to 5-oxo-ETE, which increased the levels of F-actin (i.e., polymerized actin) to 75 ± 5% above the basal level. In contrast, 5-oxo-16:2 only increased F-actin levels to 23 ± 3% above baseline (p < 0.001; Fig. 5A), whereas the maximal responses observed for 5-oxo-20:1 and 5-oxo-18:1 were 33 ± 3% (p < 0.001) and 48 ± 2% (p < 0.001) above baseline, respectively (Fig. 5C). The maximal responses to 6E,8Z,14Z-5-oxo-20:3 (43 ± 18% above control; p = 0.001) and 5-oxo-20:2 (37 ± 5% above control; p < 0.001) were also lower than that to 5-oxo-ETE by approximately 40% (Fig. 5, C and A, respectively).
Because of the variability in the maximal responses among the different analogs, EC20 rather than EC50 values were determined (Table 1). The effects of carbon chain length on potency are shown in Fig. 6A. The corresponding IC50 values for inhibition of 5-oxo-ETE-induced calcium mobilization (cf. Fig. 3D) are shown for comparison. Among the 5-oxo-dienoic acids tested, 5-oxo-18:2 was the most potent, having an EC20 (1.9 nM) significantly lower than that of its C20 homolog 5-oxo-20:2 (EC20, 10 nM; p < 0.02) and slightly lower than that of 5-oxo-ETE (EC20, 3.1 nM; N.S.) (Fig. 6A). Similar results were obtained for the desensitization by 5-oxo fatty acids of 5-oxo-ETE-induced calcium mobilization in neutrophils, with 5-oxo-ETE and 5-oxo-18:2 being more potent than 5-oxo-20:2. Of the two monoenoic acids tested, the C18 fatty acid (5-oxo-18:1; EC20, 132 nM) was also more potent in stimulating actin polymerization than the corresponding C20 compound (5-oxo-20:1; EC20, 289 nM; p < 0.05) (Fig. 6A).
The relationship between the number of olefinic double bonds and agonist potency is shown in Fig. 6B. At least one double bond is required for appreciable agonist activity, because 5-oxo-20:0 has only a very modest effect at the highest concentration tested (10 µM) (Fig. 5B). In this series, the most potent substance was 5-oxo-20:3, which had an EC20 value (1.8 nM) significantly lower than that of 5-oxo-ETE (EC20, 3.1 nM) (p < 0.05). In general, the IC50 values for calcium desensitization paralleled the EC20 values for actin polymerization, with the exception that 5-oxo-20:3 and 5-oxo-ETE had similar potencies (Fig. 6B).
Effects of 5-Oxo-20:3 and Related Compounds on Neutrophil Migration. Because of the high potency of 5-oxo-20:3 in eliciting various responses in neutrophils and eosinophils, we investigated its chemotactic effects on neutrophils. Both 5-oxo-20:3 and 8-trans-5-oxo-20:3 strongly stimulated neutrophil chemotaxis, with concentration-response curves that were virtually indistinguishable from that of 5-oxo-ETE (Fig. 7) and EC50 values between 30 and 50 nM. The maximal response for 5-oxo-20:2 was approximately 25% lower than that for 5-oxo-ETE (p < 0.05).
Formation of 5-Oxo-20:3 from Mead Acid by Neutrophils. Because of the potent effects of 5-oxo-20:3 on neutrophils and eosinophils, we investigated the possibility that it could be formed from Mead acid (i.e., 5Z,8Z,11Z-eicosatrienoic acid) by neutrophils. Mead acid was incubated with neutrophils in the presence of the calcium ionophore A23187
[GenBank]
and PMA, and the products were analyzed by RP-HPLC (Fig. 8A). The major product had a retention time (tR) of 32.9 min and a max at 235 nm (Fig. 8B), and cochromatographed with authentic chemically synthesized 5-hydroxy-6,8,11-eicosatrienoic acid (5-hydroxy-20:3). Two less polar products absorbing at 237 and 235 nm (tR 26.2 and 29.8 min, respectively), probably other monohydroxy metabolites, were also formed, but their identities were not determined. Three major products absorbing at 280 nm were also detected (Fig. 8A). The least polar of these (tR, 35.3 min) had a max at 280 nm (Fig. 8B) and cochromatographed with authentic 5-oxo-20:3. Two more polar products with tRs of 13.7 and 14.8 min had identical UV spectra typical of conjugated trienes with max values at 258, 269, and 279 nm (Fig. 8B). These products are presumably identical to 6-trans-LTB3 and 12-epi-6-trans-LTB3, which have previously been reported to be formed from Mead acid by neutrophils (Stenson et al., 1984).
|
To provide more conclusive evidence for the identities of the two major products as 5-hydroxy-20:3 and 5-oxo-20:3, these substances were purified by RP-HPLC after incubation of Mead acid with neutrophils and analyzed by mass spectrometry. Analysis of the material in the peak attributed to 5-hydroxy-20:3 by high-resolution electrospray ionization-FTMS in mass spectrometry mode gave an intense M-1 ion at m/z 321.2435 (
requires 321.2435). Collision-induced dissociation of this ion gave a series of product ions (Fig. 9A) with m/z 303.2328 (M-1-H2O; 
requires 303.2330), 285.2227 (M-2xH2O; C20H29O–1 requires 285.2224), 277.2531 (M-1-CO2; C19H33O–1 requires 277.2537), 259.2429 (M-1-CO2-H2O; 
requires 259.2431), 205.1959 (C6-C20; 
requires 205.1962), and 115.0398 (C1-C5-H; 
requires 115.0401). The ions at m/z 115 and 205 are formed by cleavage of the bond between carbons 5 and 6 and are indicative of the presence of a hydroxyl group at C5. This product ion spectrum is virtually identical to that obtained for authentic chemically synthesized 5-hydroxy-20:3 (data not shown).
|
requires 319.2279), which, when subjected to collision-induced dissociation (Fig. 9B), gave a series of product ions at m/z 301.2174 (M-1-H2O; 
requires 301.2173), 283.2065 (M-2xH2O; C20H27O–1 requires 283.2067), 275.2379 (M-1-CO2; C19H31O–1 requires 275.2380), 257.2272 (M-1-CO2-H2O; 
requires 257.2275), 247.2064 (C4-C18; C17H27O–1 requires 247.2067), 245.1909 (C4-C18-H2; C17H25O–1 requires 245.1911), 205.1959 (C6-C20; requires 205.1962), 129.0554 (C1-C6+2H; 
requires 129.0557), 113.0242 (C1-C5-H; 
requires 113.0244), and 111.0449 (129-H2O; 
requires 111.0452). The ions at m/z 113 and 205 formed by cleavage between carbons 5 and 6 are consistent with the presence of an oxo group at carbon 5. This mass spectrum is nearly identical to that obtained for authentic 5-oxo-20:3 (data not shown). |
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
11 double bond is clearly much more important than the 14 double bond, because 5-oxo-20:3 (6E,8Z,11Z) is considerably more potent than 6E,8Z,14Z-5-oxo-20:3 in inducing all of the responses investigated. Loss of the 14 double bond likewise has little impact on the effects of leukotrienes on their receptors. LTD3 was reported to be equipotent with LTD4 in stimulating contraction of guinea pig ileum (Hammarström, 1981), whereas LTB3 was nearly as potent as LTB4 in activating neutrophils (Evans et al., 1985a).
The dramatically reduced potency caused by shortening the carbon chain to 16 carbons (5-oxo-16:2) suggests that the hydrophobic -end of the molecule is important for recognition by the OXE receptor. This is in agreement with our previous finding that introduction of a polar hydroxyl group at C20 (5-oxo-20-HETE) results in a reduction in potency of nearly 100-fold (Powell et al., 1996). It is interesting to note that 5-oxo-16:2 seems to be a partial agonist, because it induced maximal responses that were only 34 ± 3% (actin polymerization) and 20 ± 8% (calcium mobilization) of those to 5-oxo-ETE. In contrast, 5-oxo-16:2 completely blocked 5-oxo-ETE-induced calcium mobilization. It is possible that further modification of the structure of this compound could result in a compound with antagonist properties.
The lack of activity of short-chain analogs of 5-oxo-ETE suggests that short-chain lipid peroxidation products such as 5-oxovaleric acid, which can be released from peroxidized phospholipids by platelet-activating factor (PAF) acetyl hydrolase (Stremler et al., 1989), would not activate the OXE receptor. In contrast, peroxidized phospholipids containing short-chain aldehydes have been shown to activate the PAF receptor (Smiley et al., 1991).
The presence of double bonds in the 6 and 8 positions of 5-oxo fatty acids is clearly important for biological activity. In the absence of any carbon-carbon double bonds (5-oxo-20:0), there is only a small degree of activity at the highest concentration tested (10 µM). The importance of the 6 double bond is consistent with the lack of activity of 6,7-dihydro-5-oxo-ETE (i.e., 5-oxo-8Z,11Z,14Z-eicosatrienoic acid), which we previously reported to be a metabolite of 5-oxo-ETE formed by a calcium/calmodulin-dependent olefin reductase in neutrophils (Berhane et al., 1998). Although the presence of a single double bond in the 6 position (i.e., 5-oxo-20:1) clearly increased activity, this compound was still approximately 100 times less potent than 5-oxo-ETE. The further addition of a 8 double bond resulted in markedly increased biological activity. However, the actual configuration of this double bond seems to be of much lesser importance, because there was little difference between the potencies of 5-oxo-20:3 (6E,8Z,11Z) and 8-trans-5-oxo-20:3 (6E,8E,11Z). This is a little surprising, because alteration of the configuration of this double bond would be expected to affect the orientation of the distal, hydrophobic portion of the molecule, which, as noted above, is important for a strong interaction with the OXE receptor. This suggests that there is sufficient flexibility in the ligand to permit the terminal part of the molecule (
C18– C20) to interact appropriately with the binding site on the receptor. We previously found that alteration of the configuration of the 8 double bond of 5-oxo-ETE (i.e., 8-trans-5-oxo-ETE) reduced potency by approximately 6-fold compared with 5-oxo-ETE. The greater impact of this modification in the case of 5-oxo-ETE may be due to the presence of the 14 double bond, which, although not required for agonist activity, might restrict the flexibility of this part of the molecule, reducing its ability to compensate for the lack of a 8 cis double bond.
The concentration-response curves for the effects of 5-oxo-ETE on calcium mobilization and CD11b expression seem to be biphasic, tending toward maxima at 1 µM and then increasing markedly at 10 µM. We conducted a limited number of experiments at higher concentrations of 5-oxo-ETE (up to 100 µM), which resulted in substantially greater, but more variable, responses, but we have not pursued this further. A similar pattern was observed for 5-oxo-18:2 and 8-trans-5-oxo-20:3. On the other hand, the responses to some of the other analogs, such as 6E,8Z,14Z-5-oxo-20:3 and 5-oxo-20:2, seemed to reach maxima, at least in the case of CD11b expression. In contrast, the concentration-response curves for the effects of most of the 5-oxo fatty acids on actin polymerization in eosinophils reached maxima within the concentration range tested. Similar results were obtained with neutrophils (data not shown). The most likely explanation for the biphasic response is that 5-oxo-ETE is a weak activator of another unrelated receptor at very high, presumably nonphysiologic, concentrations. Activation of this second receptor would then result in increased calcium mobilization and CD11b expression, without having an appreciable effect on actin polymerization. We previously found that the ability of agonists to stimulate calcium mobilization and CD11b expression in eosinophils did not necessarily parallel their ability to promote actin polymerization, with 5-oxo-ETE eliciting relatively stronger actin responses compared with other agonists such as PAF (Powell et al., 1999) and eotaxin (Powell et al., 2001).
Although it would seem conceivable that the responses to 5-oxo fatty acids that we observed are mediated principally by the OXE receptor, it is possible that interaction with other receptors could have contributed to some extent, as discussed above. Moreover, the degree of stimulation of OXE and nonOXE receptor-mediated responses may not have been the same for all of the compounds tested. The contribution of responses mediated by other receptors should be reduced by focusing more on the responses to lower concentrations of agonists by using EC20 rather than EC50 values. Furthermore, the results obtained for desensitization of 5-oxo-ETE-induced calcium mobilization used a low concentration of 5-oxo-ETE (10 nM), which would minimize activation of receptors other than the OXE receptor. Thus, inhibition of this response by 5-oxo fatty acids is probably due to their effects on the OXE receptor. The actin polymerization response to these compounds in eosinophils is also probably a good indicator of OXE receptor activation, because responses to all of the more potent agonists reached plateaus by approximately 1 µM. In general, there is very good agreement in the relative potencies of the analogs tested with respect to the different responses (Table 1).
Because of the potency of 5-oxo-20:3 in activating neutrophils and eosinophils, we were interested in determining whether it could be synthesized from a polyunsaturated fatty acid (PUFA) precursor, namely the 9 PUFA 5,8,11-eicosatrienoic acid, otherwise known as Mead acid. In contrast to 6 and 3 PUFA, which are essential fatty acids that must be supplied by the diet, 9 fatty acids are formed de novo by mammalian cells. In conditions of essential fatty acid deficiency, Mead acid accumulates in tissue lipids (Mead, 1956). Although it cannot be converted to prostanoids by cyclooxygenase because it lacks the 14,15-double bond, it can be converted to mono- and dihydroxyeicosatrienoic acids by this enzyme (Elliott et al., 1986). In contrast, Mead acid can be converted to leukotrienes (Hammarström, 1981) and 5-hydroxy-20:3 (Wei et al., 1985) by 5-LO. Although both arachidonic acid and Mead acid are transformed to LTA4 and LTA3, respectively, by 5-LO, these two substances are metabolized differently from one another. Both LTA4 and LTA3 are good substrates for LTC synthase (Hammarström, 1981), whereas only LTA4 is extensively metabolized by LTA hydrolase, and LTA3 inhibits this enzyme (Evans et al., 1985b). Thus, instead of being metabolized to LTB3 by neutrophils, Mead acid-derived LTA3 is nonenzymatically converted principally to 6-trans-LTB3 and 12-epi-6-trans-LTB3 by these cells.
The major product formed from Mead acid by neutrophils in the present study was 5-hydroxy-20:3, the identity of which was confirmed by mass spectrometry. Substantial amounts of the two 6-trans isomers of LTB3 were also detected. In addition, 5-oxo-20:3 was identified by comparison of its properties and mass spectrum with those of the authentic chemically synthesized compound. This is the first report of this compound from either a biological or chemical source, and the first documentation of its potent biological effects. Because neutrophils are unable to synthesize significant amounts of LTB3 or LTC3 from Mead acid, it would seem that the major biologically active 5-LO product formed from this PUFA by these cells is 5-oxo-20:3.
In conclusion, C18 and C20 5-oxo-6,8 fatty acids are potent activators of the OXE receptor-mediated activation of human neutrophils and eosinophils. The most potent compounds tested were 5-oxo-ETE, 5-oxo-20:3, 8-trans-5-oxo-20:3, and 5-oxo-18:2. Neutrophils convert the 9 PUFA Mead acid to one of these products, 5-oxo-20:3, which could potentially be formed and act as a proinflammatory mediator in situations of dietary essential fatty acid deficiency.
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: 5-LO, 5-lipoxygenase; LT, leukotriene; 5-HETE, 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-oxo-ETE, 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid; 5-HEDH, 5-hydroxyeicosanoid dehydrogenase; MK886, 3-[1-(p-chlorophenyl)-5-isopropyl-3-tert-butylthio-1H-indol-2-yl]-2,2-dimethylpropanoic acid; OXE, oxoeicosanoid; 5-oxo-20:5 (5-oxo-EPE), 5-oxo-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid; 5-HEPE, 5S-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid; 5-hydroxy-20:3, 5-hydroxy-6E,8Z,11Z-eicosatrienoic acid; RP-HPLC, reversed-phase high-performance liquid chromatography; 13-HODE, 13S-hydroxy-9Z,11E-octadecadienoic acid; PMA, phorbol 12-myristate 13-acetate; A23187
[GenBank]
, calcimycin; PBS, phosphate-buffered saline; NBD-phallacidin, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phallacidin; 5-oxo-14:2, 5-oxo-6E, 8Z-tetradecadienoic acid; 5-oxo-16:2, 5-oxo-6E,8Z-hexadecadienoic acid; 5-oxo-20:3, 5-oxo-6E,8Z,11Z-eicosatrienoic acid; 5-oxo-20:4 (5-oxo-ETE), 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-oxo-18:1, 5-oxo-6E-octadecenoic acid; 5-oxo-18:2, 5-oxo-6E,8Z-octadecadienoic acid; 5-oxo-20:2, 5-oxo-6E,8Z-eicosadienoic acid; 5-oxo-12:2, 5-oxo-6E,8Z-dodecadienoic acid; 5-oxoeicosanoic acid; 5-oxo-20:1, 5-oxo-6E-eicosenoic acid; 5-oxo-20:0, 5-oxoeicosanoic acid; 5-oxo-6,8,14-20:3, 5-oxo-6E,8Z,14Z-eicosatrienoic acid; tR, retention time; FTMS, Fourier transform mass spectrometry; PAF, platelet-activating factor; PUFA, polyunsaturated fatty acid; 8-trans-5-oxo-20:3, 8-trans-5-oxo-6E,8E,11Z-eicosatrienoic acid; MS, mass spectrometry.
Address correspondence to: Dr. William S. Powell, Meakins-Christie Laboratories, McGill University, 3626 St. Urbain Street, Montreal, Quebec, Canada H2X 2P2. E-mail: William.Powell{at}McGill.ca
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Almishri W, Cossette C, Rokach J, Martin JG, Hamid Q, and Powell WS (2005) Effects of prostaglandin D2, 15-deoxy-12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J Pharmacol Exp Ther 313: 64–69.
Berhane K, Ray AA, Khanapure SP, Rokach J, and Powell WS (1998) Calcium/calmodulin-dependent conversion of 5-oxoeicosanoids to 6, 7-dihydro metabolites by a cytosolic olefin reductase in human neutrophils. J Biol Chem 273: 20951–20959.
Dallaire MJ, Ferland C, Page N, Lavigne S, Davoine F, and Laviolette M (2003) Endothelial cells modulate eosinophil surface markers and mediator release. Eur Respir J 21: 918–924.
Elliott WJ, Morrison AR, Sprecher H, and Needleman P (1986) Calcium-dependent oxidation of 5,8,11-icosatrienoic acid by the cyclooxygenase enzyme system. J Biol Chem 261: 6719–6724.
Erlemann KR, Cossette C, Gravel S, Lesimple A, Lee GJ, Saha G, Rokach J, and Powell WS (2007) Airway epithelial cells synthesize the lipid mediator 5-oxo-ETE in response to oxidative stress. Free Radic Biol Med 42: 654–664.[CrossRef][Medline]
Erlemann KR, Cossette C, Gravel S, Stamatiou PB, Lee GJ, Rokach J, and Powell WS (2006) Metabolism of 5-hydroxy-6,8,11,14-eicosatetraenoic acid by human endothelial cells. Biochem Biophys Res Commun 350: 151–156.[CrossRef][Medline]
Evans J, Zamboni R, Nathaniel D, Leveille C, and Ford-Hutchinson AW (1985a) Characterization of biological properties of synthetic and biological leukotriene B3. Prostaglandins 30: 981–988.[CrossRef][Medline]
Evans JF, Nathaniel DJ, Zamboni RJ, and Ford-Hutchinson AW (1985b) Leukotriene A3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase. J Biol Chem 260: 10966–10970.
Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–1875.
Ghosh J (2004) Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315: 624–635.[CrossRef][Medline]
Ghosh J and Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95: 13182–13187.
Hamberg M and Samuelsson B (1967) On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J Biol Chem 242: 5329–5335.
Hammarström S (1981) Conversion of 5,8,11-eicosatrienoic acid to leukotrienes C3 and D3. J Biol Chem 256: 2275–2279.
Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N, Suto N, Tsunoda S, Taniguchi T, and Ohnuki T (2002) Identification of a novel eicosanoid receptor coupled to Gi/o. J Biol Chem 277: 31459–31465.
Hosoi T, Sugikawa E, Chikada A, Koguchi Y, and Ohnuki T (2005) TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun 334: 987–995.[CrossRef][Medline]
Jones CE, Holden S, Tenaillon L, Bhatia U, Seuwen K, Tranter P, Turner J, Kettle R, Bouhelal R, Charlton S, et al. (2003) Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 63: 471–477.
Khanapure SP, Shi XX, Powell WS, and Rokach J (1998) Total synthesis of a potent proinflammatory 5-oxo-ETE and its 6,7-dihydro biotransformation product. J Org Chem 63: 337–342.[CrossRef]
Mead JF and Slaton WH Jr (1956) Metabolism of essential fatty acids. III. Isolation of 5,8,11-eicosatrienoic acid from fat-deficient rats. J Biol Chem 219: 705–709.
Monneret G, Li H, Vasilescu J, Rokach J, and Powell WS (2002) 15-Deoxy-12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol 168: 3563–3569.
O'Flaherty JT, Cordes JF, Lee SL, Samuel M, and Thomas MJ (1994) Chemical and biological characterization of oxo-eicosatetraenoic acids. Biochim Biophys Acta 1201: 505–515.[Medline]
O'Flaherty JT, Kuroki M, Nixon AB, Wijkander J, Yee E, Lee SL, Smitherman PK, Wykle RL, and Daniel LW (1996) 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J Biol Chem 271: 17821–17828.
Powell WS (1980) Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 20: 947–957.[CrossRef][Medline]
Powell WS (1987) Precolumn extraction and reversed-phase high-pressure liquid chromatography of prostaglandins and leukotrienes. Anal Biochem 164: 117–131.[CrossRef][Medline]
Powell WS, Ahmed S, Gravel S, and Rokach J (2001) Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis. J Allergy Clin Immunol 107: 272–278.[CrossRef][Medline]
Powell WS, Chung D, and Gravel S (1995a) 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol 154: 4123–4132.[Abstract]
Powell WS, Gravel S, and Gravelle F (1995b) Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils. J Lipid Res 36: 2590–2598.[Abstract]
Powell WS, Gravel S, and Halwani F (1999) 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of L-selectin shedding, surface expression of CD11b, actin polymerization, and calcium mobilization in human eosinophils. Am J Respir Cell Mol Biol 20: 163–170.
Powell WS, Gravel S, Halwani F, Hii CS, Huang ZH, Tan AM, and Ferrante A (1997) Effects of 5-oxo-6,8,11,14-eicosatetraenoic acid on expression of CD11b, actin polymerization and adherence in human neutrophils. J Immunol 159: 2952–2959.[Abstract]
Powell WS, Gravel S, MacLeod RJ, Mills E, and Hashefi M (1993) Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor. J Biol Chem 268: 9280–9286.
Powell WS, Gravelle F, and Gravel S (1992) Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes. J Biol Chem 267: 19233–19241.
Powell WS, MacLeod RJ, Gravel S, Gravelle F, and Bhakar A (1996) Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol 156: 336–342.[Abstract]
Powell WS and Rokach J (2005) Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 44: 154–183.[CrossRef][Medline]
Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, and McIntyre TM (1991) Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 266: 11104–11110.
Sozzani S, Zhou D, Locati M, Bernasconi S, Luini W, Mantovani A, and O'Flaherty JT (1996) Stimulating properties of 5-oxo-eicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3. J Immunol 157: 4664–4671.[Abstract]
Stamatiou P, Hamid Q, Taha R, Yu W, Issekutz TB, Rokach J, Khanapure SP, and Powell WS (1998) 5-Oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats. J Clin Invest 102: 2165–2172.[Medline]
Stamatiou PB, Chan CC, Monneret G, Ethier D, Rokach J, and Powell WS (2004) 5-Oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte-macrophage colony stimulating factor from monocytes. J Biol Chem 279: 28159–28164.
Stenson WF, Prescott SM, and Sprecher H (1984) Leukotriene B formation by neutrophils from essential fatty acid-deficient rats. J Biol Chem 259: 11784–11789.
Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, and McIntyre TM (1989) An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 264: 5331–5334.
Sundaram S and Ghosh J (2006) Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 339: 93–98.[CrossRef][Medline]
Wei YF, Evans RW, Morrison AR, Sprechert H, and Jakschik BA (1985) Double bond requirement for the 5-lipoxygenase pathway. Prostaglandins 29: 537–545.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  P. Patel, C. Cossette, J. R. Anumolu, K.-R. Erlemann, G. E. Grant, J. Rokach, and W. S. Powell Substrate Selectivity of 5-Hydroxyeicosanoid Dehydrogenase and Its Inhibition by 5-Hydroxy-{Delta}6-Long-Chain Fatty Acids J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 335 - 341. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
; n = 4), 5-oxo-14:2 (
; n = 4), 5-oxo-18:2 (
; n = 6), 5-oxo-20:2 (
; n = 6), and 5-oxo-ETE (
; n = 14). B, effect of the number of double bonds of 5-oxo C20 fatty acids: 5-oxo-20:0 (
; n = 6), 5-oxo-20:2 (
; n = 4), 5-oxo-20:1 (
; n = 4), 5-oxo-20:3 (
